Perbak Capital Partners LLP Acquires 5,423 Shares of Bio-Rad Laboratories, Inc. $BIO

Perbak Capital Partners LLP lifted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 171.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,582 shares of the medical research company’s stock after acquiring an additional 5,423 shares during the period. Bio-Rad Laboratories makes up 0.4% of Perbak Capital Partners LLP’s holdings, making the stock its 24th biggest holding. Perbak Capital Partners LLP’s holdings in Bio-Rad Laboratories were worth $2,406,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Royal Bank of Canada lifted its position in Bio-Rad Laboratories by 25.2% in the 1st quarter. Royal Bank of Canada now owns 30,310 shares of the medical research company’s stock valued at $7,382,000 after acquiring an additional 6,100 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Bio-Rad Laboratories by 45.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company’s stock valued at $25,575,000 after purchasing an additional 32,874 shares during the last quarter. Empowered Funds LLC increased its holdings in Bio-Rad Laboratories by 14.8% during the 1st quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company’s stock worth $377,000 after purchasing an additional 199 shares in the last quarter. Jane Street Group LLC increased its holdings in Bio-Rad Laboratories by 95.3% during the 1st quarter. Jane Street Group LLC now owns 37,383 shares of the medical research company’s stock worth $9,105,000 after purchasing an additional 18,239 shares in the last quarter. Finally, KBC Group NV raised its stake in shares of Bio-Rad Laboratories by 12.7% in the second quarter. KBC Group NV now owns 1,462 shares of the medical research company’s stock worth $353,000 after purchasing an additional 165 shares during the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Up 0.4%

Bio-Rad Laboratories stock opened at $262.91 on Friday. Bio-Rad Laboratories, Inc. has a fifty-two week low of $211.43 and a fifty-two week high of $343.12. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.19 and a current ratio of 5.62. The firm’s 50-day simple moving average is $292.06 and its 200 day simple moving average is $300.22. The stock has a market cap of $7.10 billion, a PE ratio of 9.42 and a beta of 1.18.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, February 12th. The medical research company reported $2.51 EPS for the quarter, missing the consensus estimate of $2.57 by ($0.06). Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. The firm had revenue of $693.20 million during the quarter, compared to analysts’ expectations of $694.64 million. During the same quarter last year, the business posted $2.90 EPS. The company’s quarterly revenue was up 3.9% on a year-over-year basis. Research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on BIO shares. Weiss Ratings restated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Monday, December 29th. Wall Street Zen downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $358.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.